Literature DB >> 22189265

Genotype and cognitive phenotype of patients with tuberous sclerosis complex.

Agnies M van Eeghen1, Margaux E Black, Margaret B Pulsifer, David J Kwiatkowski, Elizabeth A Thiele.   

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant, multisystem disorder, which affects 1 in 6000 people. About half of these patients are affected by mental retardation, which has been associated with TSC2 mutations, epilepsy severity and tuber burden. The bimodal intelligence distribution in TSC populations suggests the existence of subgroups with distinct pathophysiologies, which remain to be identified. Furthermore, it is unknown if heterozygous germline mutations in TSC2 can produce the neurocognitive phenotype of TSC independent of epilepsy and tubers. Genotype-phenotype correlations may help to determine risk profiles and select patients for targeted treatments. A retrospective chart review was performed, including a large cohort of 137 TSC patients who received intelligence assessment and genetic mutation analysis. The distribution of intellectual outcomes was investigated for selected genotypes. Genotype-neurocognitive phenotype correlations were performed and associations between specific germline mutations and intellectual outcomes were compared. Results showed that TSC1 mutations in the tuberin interaction domain were significantly associated with lower intellectual outcomes (P<0.03), which was also the case for TSC2 protein-truncating and hamartin interaction domain mutations (both P<0.05). TSC2 missense mutations and small in-frame deletions were significantly associated with higher IQ/DQs (P<0.05). Effects related to the mutation location within the TSC2 gene were found. These findings suggest that TSC2 protein-truncating mutations and small in-frame mutations are associated with distinctly different intelligence profiles, providing further evidence that different types and locations of TSC germline mutations may be associated with distinct neurocognitive phenotypes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22189265      PMCID: PMC3330219          DOI: 10.1038/ejhg.2011.241

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  37 in total

1.  A novel missense mutation in the GTPase activating protein homology region of TSC2 in two large families with tuberous sclerosis complex.

Authors:  L Khare; G D Strizheva; J N Bailey; K S Au; H Northrup; M Smith; S L Smalley; E P Henske
Journal:  J Med Genet       Date:  2001-05       Impact factor: 6.318

2.  Characterisation of a novel TSC2 missense mutation in the GAP related domain associated with minimal clinical manifestations of tuberous sclerosis.

Authors:  K Mayer; M Goedbloed; K van Zijl; M Nellist; H-D Rott
Journal:  J Med Genet       Date:  2004-05       Impact factor: 6.318

3.  Genotype and psychological phenotype in tuberous sclerosis.

Authors:  J C Lewis; H V Thomas; K C Murphy; J R Sampson
Journal:  J Med Genet       Date:  2004-03       Impact factor: 6.318

4.  Biallelic TSC gene inactivation in tuberous sclerosis complex.

Authors:  Peter B Crino; Eleonora Aronica; Gordon Baltuch; Katherine L Nathanson
Journal:  Neurology       Date:  2010-05-25       Impact factor: 9.910

5.  Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin.

Authors:  M Nellist; M A van Slegtenhorst; M Goedbloed; A M van den Ouweland; D J Halley; P van der Sluijs
Journal:  J Biol Chem       Date:  1999-12-10       Impact factor: 5.157

6.  TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex.

Authors:  M Nellist; B Verhaaf; M A Goedbloed; A J Reuser; A M van den Ouweland; D J Halley
Journal:  Hum Mol Genet       Date:  2001-12-01       Impact factor: 6.150

7.  A family with seizures and minor features of tuberous sclerosis and a novel TSC2 mutation.

Authors:  S E O'Connor; D J Kwiatkowski; P S Roberts; R L Wollmann; P R Huttenlocher
Journal:  Neurology       Date:  2003-08-12       Impact factor: 9.910

8.  The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex.

Authors:  F J K O'Callaghan; T Harris; C Joinson; P Bolton; M Noakes; D Presdee; S Renowden; A Shiell; C N Martyn; J P Osborne
Journal:  Arch Dis Child       Date:  2004-06       Impact factor: 3.791

9.  Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.

Authors:  Attila Garami; Fried J T Zwartkruis; Takahiro Nobukuni; Manel Joaquin; Marta Roccio; Hugo Stocker; Sara C Kozma; Ernst Hafen; Johannes L Bos; George Thomas
Journal:  Mol Cell       Date:  2003-06       Impact factor: 17.970

10.  Widespread anatomical abnormalities of grey and white matter structure in tuberous sclerosis.

Authors:  K Ridler; E T Bullmore; P J De Vries; J Suckling; G J Barker; S J Meara; S C Williams; P F Bolton
Journal:  Psychol Med       Date:  2001-11       Impact factor: 7.723

View more
  30 in total

Review 1.  Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy.

Authors:  Amy R Brooks-Kayal; Kevin G Bath; Anne T Berg; Aristea S Galanopoulou; Gregory L Holmes; Frances E Jensen; Andres M Kanner; Terence J O'Brien; Vicky H Whittemore; Melodie R Winawer; Manisha Patel; Helen E Scharfman
Journal:  Epilepsia       Date:  2013-08       Impact factor: 5.864

2.  Clinical utility gene card for: tuberous sclerosis complex (TSC1, TSC2).

Authors:  Karin Mayer; Christa Fonatsch; Katharina Wimmer; Ans M W van den Ouweland; Anneke J A Maat-Kievit
Journal:  Eur J Hum Genet       Date:  2013-06-12       Impact factor: 4.246

Review 3.  New frontiers in modeling tuberous sclerosis with human stem cell-derived neurons and brain organoids.

Authors:  John D Blair; Helen S Bateup
Journal:  Dev Dyn       Date:  2019-05-23       Impact factor: 3.780

Review 4.  A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).

Authors:  Petrus J de Vries; Lucy Wilde; Magdalena C de Vries; Romina Moavero; Deborah A Pearson; Paolo Curatolo
Journal:  Am J Med Genet C Semin Med Genet       Date:  2018-08-16       Impact factor: 3.908

5.  Genotype and brain pathology phenotype in children with tuberous sclerosis complex.

Authors:  Iris E Overwater; Rob Swenker; Emma L van der Ende; Kimberley Bm Hanemaayer; Marianne Hoogeveen-Westerveld; Agnies M van Eeghen; Maarten H Lequin; Ans Mw van den Ouweland; Henriëtte A Moll; Mark Nellist; Marie-Claire Y de Wit
Journal:  Eur J Hum Genet       Date:  2016-07-13       Impact factor: 4.246

6.  A novel TSC2 mutation in a Chinese family with tuberous sclerosis complex.

Authors:  Zheng Yu; Xin Zhang; Hong Guo; Yun Bai
Journal:  J Genet       Date:  2014-04       Impact factor: 1.166

7.  Rheb protein binds CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) protein in a GTP- and effector domain-dependent manner and influences its cellular localization and carbamoyl-phosphate synthetase (CPSase) activity.

Authors:  Tatsuhiro Sato; Hitomi Akasu; Wataru Shimono; Chisa Matsu; Yuki Fujiwara; Yoshio Shibagaki; Jeffrey J Heard; Fuyuhiko Tamanoi; Seisuke Hattori
Journal:  J Biol Chem       Date:  2014-11-24       Impact factor: 5.157

8.  Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach.

Authors:  Agnies M van Eeghen; Margaret B Pulsifer; Vanessa L Merker; Ann M Neumeyer; Elmer E van Eeghen; Ronald L Thibert; Andrew J Cole; Fawn A Leigh; Scott R Plotkin; Elizabeth A Thiele
Journal:  Dev Med Child Neurol       Date:  2012-12-04       Impact factor: 5.449

9.  Early neurodevelopmental screening in tuberous sclerosis complex: a potential window of opportunity.

Authors:  Tanjala T Gipson; Gwendolyn Gerner; Siddharth Srivastava; Andrea Poretti; Rebecca Vaurio; Adam Hartman; Michael V Johnston
Journal:  Pediatr Neurol       Date:  2014-05-04       Impact factor: 3.372

Review 10.  Genetics of cognition in epilepsy.

Authors:  Robyn M Busch; Imad Najm; Bruce P Hermann; Charis Eng
Journal:  Epilepsy Behav       Date:  2014-06-25       Impact factor: 2.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.